Gilead Sciences, Inc.
NASDAQ:GILDDrug Manufacturers - General
-$2.69 today
- Market cap
- $209.59B
- Beta
- 0.33
- P/E (TTM)
- 16.5
- EPS (TTM)
- $7.42
- Dividend yield
- 2.62%
Volume 4.82M
Average 6.78M
GILD Net Income
Bottom-line profit after all expenses, interest, and taxes.
Gilead Sciences, Inc.NASDAQ: GILD
Net Income · Q2 FY2026 · quarter ended Jun 2026
Net income turns negative
Q2 FY2026 net income was -$10.5B, compared with $1.96B a year earlier. Trailing-twelve-month net income was -$3.24B. Over 3 fiscal years it compounded at +22.8% a year.
Context
- Net income amounted to 28.9% of revenue in FY2025, up 27.2 pp from a year earlier.
- Net income increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 18 analysts of -$1.24B (-114.6%) for the fiscal year ending Dec 2026, a slowdown from the +1672.9% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -$10.5B-619.3% QoQ
- Last fiscal yearDec 2025
- $8.51B+1672.9% YoY
- LTMJun 2026
- -$3.24B-151.3% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the income statement
- Latest · FY2025
- 8.51B USD
- Year-over-year change
- +1672.9%
- 4-year CAGR
- +8.1%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 8.51B | +1672.9% |
| FY2024 | 2024-12-31 | 480M | -91.5% |
| FY2023 | 2023-12-31 | 5.67B | +23.4% |
| FY2022 | 2022-12-31 | 4.59B | -26.2% |
| FY2021 | 2021-12-31 | 6.23B | — |
Net Income vs competitors
How GILD compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -151.3% is the lowest of 10, against a peer median of -6.6%.
- Net income amounts to 10.6% of revenue for GILD, versus a peer median of 15.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $26.71B USD | +93.6% | +49.0% | 33.5% | |
| LTM Sep 2026 | $16.1B USD | -35.9% | +14.3% | 16.2% | |
| LTM Jun 2026 | $12.76B USD | -6.6% | +26.4% | 22.9% | |
| LTM Sep 2026 | $10.99B USD | +16.9% | +46.1% | 17.7% | |
| LTM Sep 2026 | $10.35B USD | +333.4% | -29.1% | 15.7% | |
| LTM Jun 2026 | £4.82B GBP | +40.8% | -27.4% | 14.5% | |
| LTM Jun 2026 | $4.33B USD | -59.7% | -37.2% | 6.8% | |
| LTM Jun 2026 | €3.96B EUR | -56.6% | -2.3% | 8.1% | |
| LTM Jun 2026 | $3.17B USD | -80.7% | +7.9% | 4.8% | |
| LTM Jun 2026 | -$3.24B USD | -151.3% | +22.8% | 10.6% | |
| Peer median (excluding GILD) | — | -6.6% | +7.9% | 15.7% | |
Competitors are the stored peer set for GILD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 27.31B | 27.28B | 27.12B | 28.75B | 29.44B |
| Cost of Revenue | 6.6B | 5.66B | 6.5B | 6.25B | 6.23B |
| Gross Profit | 20.7B | 21.62B | 20.62B | 22.5B | 23.21B |
| Gross Margin | 75.8% | 79.3% | 76.0% | 78.3% | 78.8% |
| Research & Development | 4.6B | 4.98B | 5.72B | 5.91B | 5.8B |
| Selling, General & Admin | 5.25B | 5.67B | 6.09B | 6.09B | 5.71B |
| Operating Expenses | 10.79B | 14.29B | 13.01B | 20.84B | 11.51B |
| Depreciation & Amortization | 2.05B | 2.1B | 2.69B | 2.77B | 2.76B |
| EBITDA | 11.33B | 8.85B | 10.5B | 4.43B | 13.58B |
| EBITDA Margin | 41.5% | 32.4% | 38.7% | 15.4% | 46.1% |
| Operating Income | 9.92B | 7.33B | 7.61B | 1.66B | 11.7B |
| Operating Margin | 36.3% | 26.9% | 28.0% | 5.8% | 39.7% |
| Interest Income | 0 | 106M | 376M | 281M | 349M |
| Interest Expense | 1B | 935M | 944M | 977M | 1.02B |
| Other Income / Expenses | (1.64B) | (1.52B) | (746M) | (972M) | (1.91B) |
| Income Before Tax | 8.28B | 5.81B | 6.86B | 690M | 9.8B |
| Pre-Tax Margin | 30.3% | 21.3% | 25.3% | 2.4% | 33.3% |
| Income Tax Expense | 2.08B | 1.25B | 1.25B | 211M | 1.29B |
| Net Income | 6.23B | 4.59B | 5.67B | 480M | 8.51B |
| Net Margin | 22.8% | 16.8% | 20.9% | 1.7% | 28.9% |
| EPS (Basic) | 4.96 | 3.66 | 4.54 | 0.38 | 6.84 |
| EPS (Diluted) | 4.93 | 3.64 | 4.50 | 0.38 | 6.78 |
| Weighted Avg Shares | 1.26B | 1.26B | 1.25B | 1.25B | 1.24B |
| Weighted Avg Shares (Diluted) | 1.26B | 1.26B | 1.26B | 1.26B | 1.26B |
Gilead Sciences, Inc.
NASDAQ:GILD
Intrinsic Alpha fair value
Locked
Current Price
$168.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.